Compugen Ltd.NASDAQ: CGEN

Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit

· Issued by Compugen Ltd. via PR Newswire

Summary by 6ix AI

Compugen Ltd., a clinical-stage cancer immunotherapy company, will give an oral presentation on UnigenX at the 18th Annual Protein and Antibody Engineering Summit (PEGS) Europe, held November 16-19, 2026, in Lisbon, Portugal.

Key details

  • Compugen says UnigenX expands its AI-powered computational discovery platform into targeted immune activation approaches such as T cell engagers (antibodies that direct the body's T cells to attack cancer cells), and is designed to find new tumor-associated antigen targets and combinations for selectively targeting tumor cells.
  • The talk, titled "UnigenX: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation", will be given by Dr. Roy Granit, Head of Computational Discovery at Compugen, on Wednesday, November 18, 2026 at 18:30 GMT.
  • The presentation is part of the track "Advancing Multispecific Antibodies and Combination Therapy to the Clinic".

6ix AI wrote this summary from the release below and checked it against the release.

HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced an oral presentation at the 18th Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place November 16-19, 2026, in Lisbon, Portugal.

The presentation will showcase UnigenX™, an expansion of the Company's computational discovery platform into targeted immune activation modalities, such as T cell engagers, designed to discover novel tumor-associated antigen targets and combinations for selective targeting of tumor cells.

Title: UnigenX™: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation
Track: Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Speaker: Dr. Roy Granit, Head of Computational Discovery at Compugen
Date & Time: Wednesday, November 18, 2026 at 18:30 GMT
Link: PEGS Europe 2026

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum-sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Lindsey Trickett 
Email: LindseyT@cgen.com 
Tel: +1 415 373 0892

SOURCE Compugen Ltd.

View original source (PR Newswire)Compugen Ltd. on 6ix

Earlier from Compugen

All Compugen news releases